Literature DB >> 11163582

HCV genotypes and age distribution in patients of Vienna and surrounding areas.

A C Haushofer1, C Kopty, R Hauer, H Brunner, W M Halbmayer.   

Abstract

BACKGROUND: Chronic hepatitis C (CHC) can result in liver cirrhosis and hepatocellular carcinoma. Determination of the hepatitis C virus (HCV) genotype/subtype may be of prognostic value to estimate the risk of development of liver cirrhosis.
OBJECTIVE: The HCV genotype/subtype was determined in patients with CHC and possible associations with age, source of HCV transmission, duration of HCV infection, and development of liver cirrhosis were investigated. STUDY
DESIGN: A total of 250 consecutive patients with CHC were studied. HCV genotypes/subtypes were determined with a commercially available assay based on the reverse-hybridization principle. Source of HCV transmission and duration of HCV infection were taken from the patient documentation and liver cirrhosis was diagnosed by clinical, biochemical, and sonographic data.
RESULTS: HCV genotypes 1, 2, 3, 4, and 5 were found in 74.8, 2.8, 16, 5.2, and 0.4% of the patients. Most frequent subtypes were 1b (54%), 1a (15.6%), and 3a (15.6%). Patients with genotype 1 (mean, 52.8 years) or 2 (mean, 51.0 years) were significantly older than patients with genotype 3 (mean, 37.2 years) or genotype 4 (mean, 37.2 years). Patients with subtype 1b (mean, 58.1 years) were significantly older than patients with subtype 1a (mean, 40.8 years) or 3a (mean, 37.5 years). The main sources of HCV infection were intravenous drug abuse in 30.0% of all patients (genotype 1 in 53.3%; genotype 3 in 40%) or transfusion of blood and blood products in 21.6% of all patients (genotype 1 in 83.4%). The source of transmission, however, remained unknown in 44.8% of all patients. The prevalence of genotype 1 was significantly higher in patients with long duration (more than 20 years) of CHC. In none of the patients with genotype 2 or 3, duration of CHC for more than 20 years was observed. The prevalence of genotype 4 was significantly higher in patients with short duration (less than 10 years) of CHC. Liver cirrhosis was diagnosed in 13.6% of all patients (97.1% of patients with genotype 1). Patients with liver cirrhosis were significantly older compared to asymptomatic patients (mean, 63.8 vs. 51.3 years).
CONCLUSION: HCV subtype 1b was found to be the main subtype in the investigated population and is currently the major contributor to liver cirrhosis. Patients infected with subtype 1a, however, are at comparable risk for development of liver cirrhosis. In future, subtype 3a and genotype 4 may also become an increasing problem.

Entities:  

Mesh:

Year:  2001        PMID: 11163582     DOI: 10.1016/s1386-6532(00)00154-2

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  5 in total

1.  Dynamic coinfection with multiple viral subtypes in acute hepatitis C.

Authors:  Jennifer A Smith; Judith H Aberle; Vicki M Fleming; Peter Ferenci; Emma C Thomson; Peter Karayiannis; Angela R McLean; Heidemarie Holzmann; Paul Klenerman
Journal:  J Infect Dis       Date:  2010-11-10       Impact factor: 5.226

Review 2.  Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients.

Authors:  David M Novick; Mary Jeanne Kreek
Journal:  Addiction       Date:  2008-04-16       Impact factor: 6.526

Review 3.  Molecular and contextual markers of hepatitis C virus and drug abuse.

Authors:  Paul Shapshak; Charurut Somboonwit; Lydia N Drumright; Simon D W Frost; Deborah Commins; Timothy L Tellinghuisen; William K Scott; Robert Duncan; Clyde McCoy; J Bryan Page; Brian Giunta; Francisco Fernandez; Elyse Singer; Andrew Levine; Alireza Minagar; Oluwadayo Oluwadara; Taiwo Kotila; Francesco Chiappelli; John T Sinnott
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

Review 4.  Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention.

Authors:  Lucas Wiessing; Marica Ferri; Bart Grady; Maria Kantzanou; Ida Sperle; Katelyn J Cullen; Angelos Hatzakis; Maria Prins; Peter Vickerman; Jeffrey V Lazarus; Vivian D Hope; Catharina Matheï
Journal:  PLoS One       Date:  2014-07-28       Impact factor: 3.240

5.  Efficacy and safety of pegylated interferon α and ribavirin in patients monoinfected with HCV genotype 4.

Authors:  Dorota Kozielewicz; Anna Grabińska; Grzegorz Madej; Magdalena Wietlicka-Piszcz
Journal:  Prz Gastroenterol       Date:  2018-03-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.